|
|
|
|
|
|
|
|
Progress in PARP inhibitors beyond BRCA mutant recurrent ovarian cancer? - The Lancet Oncology
(not open access)
Published: 28 November 2016
References
References
- Nielsen, FC, van Overeem Hansen, T, and Sørensen, CS. Hereditary breast and ovarian cancer: new genes in confined pathways. Nat Rev Cancer. 2016; 16: 599–612
- Konstantinopoulos, PA, Ceccaldi, R, Shapiro, GI, and D'Andrea, AD. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2015; 5: 1137–1154
- Ledermann, J, Harter, P, Gourley, C et al. Olaparib
maintenance therapy in patients with platinum-sensitive relapsed serous
ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA
status in a randomised phase 2 trial. Lancet Oncol. 2014;
15: 852–861
- Summary
- | Full Text
- | Full Text PDF
- | PubMed
- | Scopus (254)
- Kaufman, B, Shapira-Frommer, R, Schmutzler, RK et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015; 33: 244–250
- Gelmon, KA, Tischkowitz, M, Mackay, H et al. Olaparib
in patients with recurrent high-grade serous or poorly differentiated
ovarian carcinoma or triple-negative breast cancer: a phase 2,
multicentre, open-label, non-randomised study. Lancet Oncol. 2011;
12: 852–861
- Summary
- | Full Text
- | Full Text PDF
- | PubMed
- | Scopus (433)
- Abkevich, V, Timms, KM, Hennessy, BT et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 2012; 107: 1776–1782
- Watkins, JA, Irshad, S, Grigoriadis, A, and Tutt, AN. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res. 2014; 16: 211
- Swisher, EM, Lin, KK, Oza, AM et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncology. 2016; (published online Nov 28.)http://dx.doi.org/10.1016/S1470-2045(16)30559-9.
- Coleman, RL, Swisher, EM, and Oza, AM. Refinement of prespecified cutoff for genomic loss of heterozygosity in ARIEL2 part 1: a phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma. Proc Am Soc Clin Oncol. 2016; 34 (abstr 5540.)
- Mirza, MR, Monk, BJ, Herrstedt, J et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016; (published online Oct 7.)
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.